Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Novel ADAMTS13 Fusion Construct Targets Dual Mechanisms in Immune-Mediated TTP – JTH
Nov 21, 2026, 06:52

Novel ADAMTS13 Fusion Construct Targets Dual Mechanisms in Immune-Mediated TTP – JTH

Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Yunpeng Xue et al, adding:

“ADAMTS 13 fusion constructs with dual activity against von Willebrand factor: a novel strategy for immune mediated thrombotic thrombocytopenic purpura

This laboratory study combines an autoantibody-resistant ADAMTS 13 variant with a single-domain antibody targeting active von Willebrand factor.

The fusion construct retained VWF cleaving activity while reducing platelet VWF interactions.

In assays using plasma from patients with immune mediated TTP, the engineered construct showed greater resistance to inhibitory autoantibodies.

The work explores a dual action strategy against the molecular drivers of iTTP.

Patient efficacy and safety have not been established by these experimental findings.”

Title: ADAMTS-13 fusion constructs with dual activity against von Willebrand factor: a novel strategy for immune-mediated thrombotic thrombocytopenic purpura

Authors: Yunpeng Xue, Mark Roest, Steven J. Humphreys, Lisa N. van der Vorm, Joke Konings, Piet Meijer, Claire S. Whyte, Philip G. de Groot, Nicholas A. Arce, Renhao Li, Nicola J. Mutch, Bas de Laat, Dana HuskensNovel ADAMTS13 Fusion Construct Targets Dual Mechanisms in Immune-Mediated TTP - JTH

Stay updated on all scientific advances with Hemostasis Today.